Entering text into the input field will update the search result below

Chimerix terminates patent license deal with UC

Jul. 03, 2019 2:22 PM ETChimerix, Inc. (CMRX) StockCMRXBy: Jason Aycock, SA News Editor1 Comment
  • In an SEC filing, Chimerix (NASDAQ:CMRX) notes that it terminated its license agreement with the Regents of the University of California.
  • That license was formed in 2002 and covers the university's patent rights in inventions related to lipid-conjugated antiviral compounds and their use -- which include patents covering CMX001/brincidofovir, set to expire in 2020.
  • The license's end doesn't affect Chimerix's solely owned patents covering CMX001/brincidofovir composition of matter, set to expire in 2034.

Recommended For You

About CMRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CMRX--
Chimerix, Inc.